A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

被引：0

作者：

Crombie, Jennifer L. ^{[1
]}

Ryan, Christine E. ^{[2
]}

Ren, Yue ^{[2
]}

Tyekucheva, Svitlana ^{[3
]}

Carey, Celeste ^{[4
]}

Zou, Aaron ^{[4
]}

Normilus, Samantha ^{[4
]}

Montegaard, Josie ^{[4
]}

Soumerai, Jacob D. ^{[5
]}

Bhandari, Shruti ^{[6
]}

Arnason, Jon E. ^{[7
]}

Alencar, Alvaro J. ^{[8
]}

Kim, Austin I. ^{[9
]}

Parry, Erin M. ^{[2
]}

Armand, Philippe ^{[2
]}

Fisher, David C. ^{[2
]}

Brown, Jennifer R. ^{[10
]}

Davids, Matthew S. ^{[11
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[4] Dana Farber Canc Inst, Boston, MA USA

[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[6] Northern Light Canc Care, Dept Hematol & Oncol, Brewer, ME USA

[7] Beth Israel Deaconess Med Ctr, Boston, MA USA

[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Div Hematol, Miami Beach, FL USA

[9] Dana Farber Canc Inst, Dept Med Oncol, Newton Ctr, MA USA

[10] Dana Farber Canc Inst, Dept Med Oncol, Newton, MA USA

[11] Dana Farber Canc Inst Inc, Dept Med Oncol, Boston, MA USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199234

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4628 / 4629

页数：2

共 50 条

[1] Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)
Ryan, Christine E.
Crombie, Jennifer L.
Tyekucheva, Svitlana
McDonough, Mikaela M.
Montegaard, Josie S.
Kim, Austin, I
Soumerai, Jacob D.
Alencar, Alvaro J.
Bhandari, Shruti
Fisher, David C.
Brown, Jennifer R.
Davids, Matthew S.
BLOOD, 2022, 140 : 9871 - 9872
[2] Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Jain, Nitin
Keating, Michael J.
Thompson, Philip A.
Burger, Jan A.
Ferrajoli, Alessandra
Estrov, Zeev E.
Borthakur, Gautam M.
Takahashi, Koichi
Bose, Prithviraj
Fowler, Nathan H.
Kadia, Tapan M.
Daver, Naval G.
Konopleva, Marina Y.
Alvarado, Yesid
Yilmaz, Musa
DiNardo, Courtney D.
Ohanian, Maro
Pemmaraju, Naveen
Jabbour, Elias
Sasaki, Koji
Kanagal-Shamanna, Rashmi
Patel, Keyur
Jorgensen, Jeffrey L.
Wang, Sa A.
Garg, Naveen
Wang, Xuemei
Sondermann, Katrina
Cruz, Nichole
Wei, Chongjuan
Ayala, Ana
Plunkett, William
Kantarjian, Hagop M.
Gandhi, Varsha
Wierda, William G.
BLOOD, 2019, 134
[3] Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome
Crombie, Jennifer L.
Tyekucheva, Svitlana
Wang, Zixu
Savell, Alexandra
Brennan, Lisa
Lowney, Jessica
Francoeur, Karen
Montegaard, Josie
Kim, Austin I.
Soumerai, Jacob D.
Arnason, Jon E.
Cruz, Allan Louie
Berg, Sigrid
Fisher, David C.
Brown, Jennifer R.
Davids, Matthew S.
BLOOD, 2020, 136
[4] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Rogers, Kerry A.
Thompson, Philip A.
Allan, John N.
Coleman, Morton
Sharman, Jeff P.
Cheson, Bruce D.
Izumi, Raquel
Frigault, Melanie M.
Quah, Cheng
Raman, Rakesh K.
Wang, Min Hui
Kipps, Thomas J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S282 - S283
[5] A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Barr, Paul M.
Hill, Brian T.
Ma, Shuo
Baran, Andrea M.
Bui, Andrew
Meacham, Philip J.
Morrison, Ashley
Liesveld, Jane L.
Mulford, Deborah A.
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Friedberg, Jonathan W.
Zent, Clive S.
BLOOD, 2019, 134
[6] A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL
Crombie, Jennifer L.
Tyekucheva, Svitlana
Savell, Alexandra
Francoeur, Karen
Choiniere, Mark
Montegaard, Josie
Soumerai, Jacob D.
Arnason, Jon E.
Fisher, David C.
Brown, Jennifer R.
Davids, Matthew S.
BLOOD, 2019, 134
[7] Characterization and predictors of sleep disturbance in patients with relapsed/refractory chronic lymphocytic leukemia (r/r CLL)
Westbrook, Travis D.
Maddocks, Kami J.
Andersen, Barbara L.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] Acquired Mutations in Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) That Progressed in the ALPINE Study
Brown, Jennifer R.
Li, Jessica
Eichhorst, Barbara F.
Lamanna, Nicole
O'Brien, Susan M.
Tam, Constantine S.
Qiu, Luqui
Ramakrishnan, Vanitha
Huang, Ruiqi
Shi, Yang
Idoine, Adam
Salmi, Tommi
Cohen, Aileen Cleary
Shadman, Mazyar
BLOOD, 2023, 142
[9] Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results.
Mato, Anthony R.
Sharman, Jeff P.
Biondo, Juliana
Wu, Mei
Mun, Yong
Kim, Su Young
Humphrey, Kathryn
Boyer, Michelle
Zhu, Qian
Seymour, John F.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Comparative analysis of targeted therapies in relapsed/refractory chronic lymphocytic leukemia (R/R CLL)
Mato, Anthony
Roeker, Lindsey
Eyre, Toby
Ujjani, Chaitra
Lamanna, Nicole
Hill, Brian
Barr, Paul
Lansigan, Erick
Cheson, Bruce D.
Yazdy, Maryam
Allan, John
Rhodes, Joanna
Kennard, Kaitlin
Schuster, Steven
Nabhan, Chadi
Skarbnik, Alan
Goy, Andre
Dorsey, Colleen
Goodfriend, Julie
Coombs, Catherine
Tuncer, Hande H.
Pagel, John
Jacobs, Ryan
Kirkwood, Amy
Winter, Allison
Schuh, Anna
Bailey, Neil
Sitlinger, Andrea
Shadman, Mazyar
Fox, Christopher
Brander, Danielle
LEUKEMIA & LYMPHOMA, 2020, 61 : 193 - 195

← 1 2 3 4 5 →